ACD and Leica to comarket RNA ISH assays
November 2014—Leica Biosystems and Advanced Cell Diagnostics announced the comarketing of ACD’s RNAscope LS ISH assays using Leica’s Bond Rx research-use-only staining platform.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
CE marking for Ventana system, 11/14
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
Microplates, 11/14
November 2014—BrandTech Scientific announced the availability of inertGrade microplates for the cultivation of nonadherent cell lines, spheroids, and stem cells in a 96-well plate format. The polystyrene plates are treated with a proprietary hydrogel that creates a hydrophobic interface between the surface of the plastic and cellular material to inhibit cell and protein attachment.
Anti-human protein antibodies, 11/14
November 2014—The Binding Site offers a line of anti-human blood protein antibodies for use by clinical and life science researchers, medical laboratory professionals, and in vitro diagnostic manufacturers.
FDA OKs marketing of AKI risk-assessment test, 11/14
November 2014—The Food and Drug Administration is allowing the marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury in the 12 hours following administration of the test. Early knowledge that a patient is likely to develop AKI may prompt closer patient monitoring and help prevent permanent kidney damage or death, according to the agency.
CE marking for Ventana system, 11/14
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
GenoLogics enters agreement with Illumina, 11/14
November 2014—GenoLogics has been selected by Illumina as the laboratory information management system provider to support customers of the HiSeq X Ten sequencing system. Under the agreement, the companies will provide support for HiSeq X Ten whole-genome workflows and analysis pipelines, including those to be used inside of Illumina.
Molecular diagnostics platform, 11/14
November 2014—Biocartis announced the launch of its flagship molecular diagnostics system, Idylla. With Idylla, Biocartis also released its first oncology assay, the Idylla BRAF Mutation Test. Both Idylla and the Idylla BRAF Mutation Test have obtained CE-IVD marking.
Microsampling device, 10/14
October 2014—Neoteryx announced the launch of the Mitra (RUO) Microsampling Device for the collection, transport, storage, and analysis of biological fluids. In seconds, the research-use-only Mitra microsampler consistently collects 10 µL of fluid while eliminating the volumetric blood hematocrit bias typically associated with the dried blood spotting technique.
AstraZeneca collaborations, 10/14
October 2014—AstraZeneca announced it has entered into a collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small cell lung cancer.